BU-NOT-SET

CONTACT US
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand
  • Drug substance
Eyes
Insight
A CDMO’s insight into the pharma M&A landscape
  • Industry trends
Eyes
Insight
Recipharm’s continuous global support throughout the COVID-19 pandemic
  • Industry trends
Eyes
Insight
Is outsourcing the most viable pathway for innovators?
  • Manufacturing
Meeting
Insight
Developing a generic prolonged-release isosorbide-5-mononitrate tablet
  • Drug product
Two lab workers
Case study
Recipharm Wins two 2020 CMO Leadership Awards
  • Industry trends
Eyes
Insight
Recipharm’s global teams support and engage with their local communities in the fight against COVID-19
  • Corporate
Eyes
Insight
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
  • Manufacturing
Eyes
Insight
Recipharm 25 years
  • Corporate
24 years
Brochure
Case study
  • Drug product
Optimising a prolonged release fixed dose combination product
Webinar
  • Analytical chemistry
  • Drug product
Ensuring stability excellence for global consumer and OTC products
Insight
  • Industry trends
The impact of the COVID-19 pandemic on global pharmaceutical growth
Insight
  • Industry trends
COVID-19: a year of unprecedented change
Insight
  • Drug product
Oral solids: market and technology trends
Fact sheet
  • Drug product
Oral modified release
Fact sheet
  • Drug product
Semi-solids an overview of current regulatory requirement
Insight
  • Drug substance
API relocation strategies for CDMO’s
Fact sheet
  • Drug product
  • Manufacturing
Clinical trial material